A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.

The present invention provides a pharmaceutical combination comprising a CRAF inhibitor plus (i) an ERK inhibitor or (ii) a MEK inhibitor, for use in the treatment of non-small cell lung cancer (NSCLC) where the carcinoma cells of the NSCLC harbor a mutation of BRAF other than the BRAF V600E-mutant, and related invention aspects. The present invention also provides dosages and dosage regimens of a CRAF inhibitor with an ERK inhibitor or with trametinib for use in the treatment of BRAF V600 mutant (e.g. BRAF V600E mutant) NSCLC.

The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogenic mi-crobes that has localized on the mucocutaneous lining of the conjunctiva, mouth and nose, lung, or gastrointestinal tract. The cyclodex-trin may bind the viral particles and/or disrupt viral entry mechanisms by removing cholesterol from viral particles to reduce infectivity. Cyclodextrins also may facilitate removal of the viral cholesterol molecules, thus rendering them less viable. Cyclodextrin activity may be further enhanced when used in combination with certain minerals and/or antioxidant compounds.

The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogenic mi-crobes that has localized on the mucocutaneous lining of the conjunctiva, mouth and nose, lung, or gastrointestinal tract. The cyclodex-trin may bind the viral particles and/or disrupt viral entry mechanisms by removing cholesterol from viral particles to reduce infectivity. Cyclodextrins also may facilitate removal of the viral cholesterol molecules, thus rendering them less viable. Cyclodextrin activity may be further enhanced when used in combination with certain minerals and/or antioxidant compounds.

The present invention relates to nano-resin particles that are suitable for pharmaceutical use and their use in the pharmaceutical field. The present invention provides nano-sized resin particles having a particle size distribution characterized in that D.sub.90 value is between 200 nanometers to 900 nanometer and D.sub.10 value is not less than 50 nanometers, wherein the nano-resin particles are in pure form and safe for pharmaceutical use. The present invention further relates to pharmaceutical compositions comprising these purified nano-resin particles and their use in the treatment of diseases. The present invention further provides a process for preparing purified, nano-sized resin particles that are suitable for pharmaceutical use, the process comprising steps of: (i) washing an ion exchange resin and suspending in an aqueous liquid, (ii) subjecting the suspension of (i) to wet milling for a period such that the particles have a particle size distribution characterized in that the D.sub.90 value is between 200 nanometers to 900 nanometers and D.sub.10 value is not less than 50 nanometers, (iii) subjecting the suspension of (ii) to purification to remove impurities, (iv) drying the purified suspension to obtain nano-resin particles in the form of dry powder.

The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.

The present invention relates to a process for preparing a solid composition comprising at least one active ingredient and at least one excipient comprising: i) mixing said at least one active ingredient and said at least one excipient in a granulator to obtain wet granules; ii) spreading wet granules on a tray and let stand for 2 to 24 hours between 15 and 25° C.; iii) compressing granules obtained after step ii) with a tablet press; and iv) collecting the solid composition. The invention further relates a solid composition obtained by such process.

A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.

A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.